Huahai Pharmaceutical's Subsidiary Huaao Bio Announces Capital Increase and Introduction of Investor Haijing Venture Capital

Huahai Pharmaceutical (600521.SH) announced that, in line with the company’s overall development plan and to further accelerate the strategic layout of its biologic innovation drugs, enhance the company’s core competitiveness and sustainable development capabilities, and strengthen the operational capacity of its subsidiary Shanghai Huaota Biopharmaceutical Co., Ltd. (referred to as “Huaota”), the company plans to introduce an investor, Linhai Haijing Venture Capital Partnership (Limited Partnership) (referred to as “Haijing Venture Capital”), to subscribe for 20 million new shares of Huaota. After this capital increase and share expansion, Huaota’s registered capital will increase from 300 million yuan to 320 million yuan, and its total share capital will increase from 300 million shares to 320 million shares.